Biotech firms those smaller pharmaceutical companies with limited products on the market and/or initial products in the early stages of research and development represent, arguably, the hottest future business in the United States and globally.As such, New Jersey's emerging position as one of the nation's leading biotech centers promises a significant economic impact.According to the Biotechnology Council of New Jersey, Inc., the state currently houses approximately 124 biotech firms within its borders, ranking fourth in the nation in terms of biotech presence.Several notable firms are maturing here, including Enzon Pharmaceuticals, Celgene, Pharmacopeia and Medarex, to name a few. Each has products moving through clinical phases that are expected to elevate to the next level in the near future.New Jersey's strong educational infrastructure, which continually spins out new research and a talented labor force, and the state's long standing pharmaceutical corporate base,